Compare ZS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZS | WST |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0B | 20.2B |
| IPO Year | 2018 | N/A |
| Metric | ZS | WST |
|---|---|---|
| Price | $230.99 | $271.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 34 | 10 |
| Target Price | $323.73 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 2.4M | 661.3K |
| Earning Date | 11-25-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 0.33% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | N/A | ★ 6.75 |
| Revenue | $2,833,272,000.00 | ★ $3,017,900,000.00 |
| Revenue This Year | $26.93 | $7.01 |
| Revenue Next Year | $19.33 | $6.20 |
| P/E Ratio | ★ N/A | $39.63 |
| Revenue Growth | ★ 23.24 | 4.92 |
| 52 Week Low | $164.78 | $187.43 |
| 52 Week High | $336.99 | $348.90 |
| Indicator | ZS | WST |
|---|---|---|
| Relative Strength Index (RSI) | 24.29 | 49.70 |
| Support Level | $237.77 | $265.39 |
| Resistance Level | $245.12 | $274.56 |
| Average True Range (ATR) | 7.39 | 7.11 |
| MACD | -0.87 | -0.59 |
| Stochastic Oscillator | 1.44 | 38.85 |
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.